{"id":"NCT01728324","sponsor":"Boehringer Ingelheim","briefTitle":"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","officialTitle":"A Phase III Randomised, Partially Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Chronic Genotype 1 Hepatitis C Infection in an Extended Population of Treatment naïve Patients That Includes Those Ineligible to Receive Peginterferon","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2014-02","completion":"2015-01","firstPosted":"2012-11-19","resultsPosted":"2016-02-12","lastUpdate":"2016-02-12"},"enrollment":496,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"BI 207127-placebo: 8-week treatment","otherNames":[]},{"type":"DRUG","name":"Ribavirin: 24-week treatment","otherNames":[]},{"type":"DRUG","name":"BI 207127: 24-week treatment","otherNames":[]},{"type":"DRUG","name":"Faldaprevir: 24-week treatment","otherNames":[]},{"type":"DRUG","name":"Faldaprevir: 24-week treatment","otherNames":[]},{"type":"DRUG","name":"Ribavirin-placebo: 8-week treatment","otherNames":[]},{"type":"DRUG","name":"BI 207127: 24-week treatment","otherNames":[]},{"type":"DRUG","name":"Faldaprevir-placebo: 8-week treatment","otherNames":[]},{"type":"DRUG","name":"Faldaprevir: 16-week treatment","otherNames":[]},{"type":"DRUG","name":"Ribavirin: 16-week treatment","otherNames":[]},{"type":"DRUG","name":"RBV: 24-week treatment","otherNames":[]},{"type":"DRUG","name":"BI 207127: 16-week treatment","otherNames":[]}],"arms":[{"label":"Randomised 24-week arm","type":"EXPERIMENTAL"},{"label":"Randomised 16-week arm","type":"EXPERIMENTAL"},{"label":"Allocated 24-week arm","type":"EXPERIMENTAL"}],"summary":"The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD FDV and RBV for 16 or 24 weeks in target chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.","primaryOutcome":{"measure":"SVR12 Rates With Historical Control","timeFrame":"12 Week (post-treatment)","effectByArm":[{"arm":"24-wk Non-cirrhotic (NC)+24-wk Cirrhotic (CR) Treatment Group","deltaMin":79.95,"sd":null},{"arm":"16-wk Non-cirrhotic (NC)+24-wk Cirrhotic (CR) Treatment Group","deltaMin":76.68,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"},{"comp":"OG001","p":"0.0020"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":109,"countries":["United States","Australia","Belgium","Canada","France","Germany","Greece","Italy","New Zealand","Portugal","Spain","United Kingdom"]},"refs":{"pmids":["27920566"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":211},"commonTop":["Nausea","Fatigue","Vomiting","Diarrhoea","Pruritus"]}}